Nasdaq exas.

Market Activity Funds + ETFs After-Hours Quotes News + Insights P/E & PEG Ratios Nasdaq MarketSIte Do Not Sell My Personal Information (CA Residents Only) © 2022, …WebFeb 27, 2018 · ADVISORY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- What: Exact Sciences Corp. (Nasdaq:EXAS), a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer, will open the Nasdaq Stock Market remotely from the Cologuard Classic, a PGA TOUR Champions event in Tucson, Arizona. Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer ...1. Exact Sciences. Exact Sciences' goal is to eradicate cancer. Perhaps that's too optimistic, but the company could play a role in reducing cancer deaths through its diagnostic solutions.

EXAS earnings call for the period ending March 31, 2023. Image source: The Motley Fool. Exact Sciences ( EXAS 0.14% ) Q1 2023 Earnings Call May 09, 2023 , 5:00 p.m. ET

A market research report on Exact Sciences ( NASDAQ: EXAS) from Cathie Wood's ARK-Invest ( ARKK) ( ARKG) has caught a lot of attention with another assertive call on the share price performance in ...This year, Exact Sciences (NASDAQ: EXAS) expects its revenue will total just under $2.1 billion. That means that in just five years, its top line will have grown by an incredible 683%.

Apr 24, 2023 · Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ... Get the latest Exscientia PLC (EXAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.In trading on Friday, shares of EXACT Sciences Corp. (Symbol: EXAS) crossed below their 200 day moving average of $46.11, changing hands as low as $45.88 per share. EXACT Sciences Corp. shares are ...Apr 27, 2022 3:33PM EDT. A mong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Qualcomm Inc (Symbol: QCOM), where a total of 80,465 ...Feb 10, 2023 · As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ...

May 11, 2023 · Shares of Exact Sciences ( EXAS 4.73%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...

Turning to the calls side of the option chain, the call contract at the $51.00 strike price has a current bid of $3.30. If an investor was to purchase shares of EXAS stock at the current price ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...On March 9, 2023, Citigroup upgraded their outlook for EXACT Sciences (NASDAQ:EXAS) from Neutral to Buy.. Analyst Price Forecast Suggests 15.57% Upside. As of March 9, 2023, the average one-year ...EXAS missed the consensus earnings per share in the 1st calendar quarter of 2020 by -5.26%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for EXAS is -92.27 vs. an ...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ...

The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.Exact Sciences Corp (NASDAQ:EXAS) Intrinsic Valuation. Check if EXAS is overvalued or undervalued under the bear, base, and bull scenarios of the company's ...In the latest trading session, Exact Sciences (EXAS) closed at $66.26, marking a -1.27% move from the previous day. This move lagged the S&P 500's daily gain of 0.57%. Elsewhere, the Dow gained 0. ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ...

The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...

Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. ... To EXAS's credit, this debt issuance has been opportunistic CV offerings, at ...May 15, 2023 · Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer ... EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ... Get the latest Exscientia PLC (EXAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions."Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. 67.03 USD R +3.03 +4.73%. At close at Dec 1, 16:58 UTC-8. USD. No trades. See on …WebExact Sciences (NASDAQ: EXAS) Stock Quote. Follow Insider Trades Visit website. Last Trade: US$64.00 -1.06 -1.63. Volume: 1,800,029. 5-Day Change: -1.75%. YTD ...Shares of EXAS stock opened at $67.03 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.13 and a current ratio of 2.41. The firm has a market cap of $12.12 billion, a ...EXAS U.S.: Nasdaq Exact Sciences Corp. Watch list NEW Set a price target alert Open Last Updated: Nov 20, 2023 2:33 p.m. EST Real time quote $ 67.73 1.43 2.15% Previous …Web

Exact Sciences Corp (NASDAQ:EXAS) Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73.Web

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...

Find the latest press releases from Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Thank you for joining us for Exact Sciences third quarter 2023 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO, and Jeff Elliott, our Chief Financial Officer ...Exact Sciences Corporation Common Stock (EXAS) Historical Closing Prices - View free historical Nasdaq official closing price data at Nasdaq.com.Exact Sciences (NASDAQ:EXAS) stands out as a key player in the field of cancer detection and diagnostics, attracting the attention of investors seeking innovative opportunities.Its recent ...About · Highlight. A leading provider of cancer screening and diagnostic tests · Exchange. NASDAQ · Listing Date. 01/30/2001 · Established Date. 02/10/1995.Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 67.03 +3.03 (+4.73%) At close: 04:00PM EST. 67.10 +0.07 (+0.10%) After hours: 07:58PM...Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 67.03 +3.03 (+4.73%) At close: 04:00PM EST. 67.03 0.00 (0.00%) After hours: 04:03PM EST.Exact Sciences Corporation (NASDAQ:EXAS) has a market capitalization of $11.574 billion. Artisan Small Cap Fund made the following comment about Exact …WebMADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will ...

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) saw a large growth in short interest during the month of October.As of October 15th, there was short interest totalling 8,170,000 shares, a ...The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...1 Mar 2017 ... Exact sciences rings the Nasdaq Closing Bell! $EXAS #CRCcountdown.Instagram:https://instagram. etnnee stock newsmoving stocksprtax Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.3 Nov 2023 ... Exact Sciences (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, visits the Nasdaq MarketSite in Times Square. psychedelics etfmutf fmagx MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will ... batt stock price Analyst's Opinion · Consensus Rating. Exact Sciences has received a consensus rating of Moderate Buy. · Price Target Upside/Downside. According to analysts' ...According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.